Reduced skin elasticity can make cellulite more prominent, as the skin loses its ability to smoothly cover underlying fat deposits
Regulatory Timeline: From Preclinical Promise to Category 2 Restriction The full arc of AOD-9604's regulatory history spans roughly 25 years
Key pathophysiologic mechanisms include: Mucosal barrier dysfunction: Impaired epithelial tight junctions allow bacterial translocation, triggering innate immune activation T-helper cell dysregulation: Predominantly Th1 and Th17 pathways drive chronic inflammation via TNF-, IL-12, IL-23 the basis for biologic therapy targets Transmural inflammation: Unlike UC (mucosal only), CD involves all layers: mucosa submucosa muscularis propria serosa Granuloma formation: Non-caseating granulomas are pathognomonic but present in only ~3050% of biopsies Fibrosis and stricture: Chronic inflammation activates myofibroblasts collagen deposition luminal narrowing obstructive symptoms Fistula formation: Transmural ulcers penetrate serosa form sinus tracts connect to adjacent bowel, bladder, vagina, or skin 7

Everyone responds differently to medications Dosage adjustments may be necessary based on individual response to the medication, including weight loss progress, blood sugar control, and tolerability of side effects